transmembrane protein adipocyte associated 1Genealiases: GPR175 · TMEM227 · TPRA40
Q-omics provides the consensus-scored TPRA1 profile across patient tissues and cancer cell-line models. TPRA1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TPRA1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TPRA1 RNA expression shows 18,363 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, HNSC, and ACC as cancer lineages where TPRA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPRA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPRA1 survival associations across molecular data types. TPRA1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPRA1 RNA expression–survival associations across cancer types. High TPRA1 expression shows unfavorable associations in BRCA, LIHC, KIRC, KICH and LGG, but favorable associations in UVM. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for TPRA1 RNA expression.
This table summarizes TPRA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TPRA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPRA1 shows higher tumor expression in HNSC, COAD, BLCA, LIHC, STAD and CHOL. The HNSC box plot shows higher TPRA1 RNA expression in tumor versus normal tissue (log2 FC = +1.045, t-test p < 0.001).
This table shows molecular features associated with TPRA1 in patient tissues and cancer cell lines. In patient samples, TPRA1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TPRA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
